Physical exercise for people with Parkinson's disease: a systematic review and network meta-analysis.


Journal

The Cochrane database of systematic reviews
ISSN: 1469-493X
Titre abrégé: Cochrane Database Syst Rev
Pays: England
ID NLM: 100909747

Informations de publication

Date de publication:
05 01 2023
Historique:
entrez: 5 1 2023
pubmed: 6 1 2023
medline: 10 1 2023
Statut: epublish

Résumé

Physical exercise is effective in managing Parkinson's disease (PD), but the relative benefit of different exercise types remains unclear. To compare the effects of different types of physical exercise in adults with PD on the severity of motor signs, quality of life (QoL), and the occurrence of adverse events, and to generate a clinically meaningful treatment ranking using network meta-analyses (NMAs). An experienced information specialist performed a systematic search for relevant articles in CENTRAL, MEDLINE, Embase, and five other databases to 17 May 2021. We also searched trial registries, conference proceedings, and reference lists of identified studies up to this date. We included randomized controlled trials (RCTs) comparing one type of physical exercise for adults with PD to another type of exercise, a control group, or both. Two review authors independently extracted data. A third author was involved in case of disagreements.  We categorized the interventions and analyzed their effects on the severity of motor signs, QoL, freezing of gait, and functional mobility and balance up to six weeks after the intervention using NMAs. Two review authors independently assessed the risk of bias using the risk of bias 2 (RoB 2) tool and rated the confidence in the evidence using the CINeMA approach for results on the severity of motor signs and QoL. We consulted a third review author to resolve any disagreements. Due to heterogeneous reporting of adverse events, we summarized safety data narratively and rated our confidence in the evidence using the GRADE approach. We included 156 RCTs with a total of 7939 participants with mostly mild to moderate disease and no major cognitive impairment. The number of participants per study was small (mean 51, range from 10 to 474). The NMAs on the severity of motor signs and QoL included data from 71 (3196 participants), and 55 (3283 participants) trials, respectively. Eighty-five studies (5192 participants) provided safety data. Here, we present the main results. We observed evidence of beneficial effects for most types of physical exercise included in our review compared to a passive control group. The effects on the severity of motor signs and QoL are expressed as scores on the motor scale of the Unified Parkinson Disease Rating Scale (UPDRS-M) and the Parkinson's Disease Questionnaire 39 (PDQ-39), respectively. For both scales, higher scores denote higher symptom burden. Therefore, negative estimates reflect improvement (minimum clinically important difference: -2.5 for UPDRS-M and -4.72 for PDQ-39). Severity of motor signs The evidence from the NMA (71 studies; 3196 participants) suggests that dance has a moderate beneficial effect on the severity of motor signs (mean difference (MD) -10.32, 95% confidence interval (CI) -15.54 to -4.96; high confidence), and aqua-based, gait/balance/functional, and multi-domain training might have a moderate beneficial effect on the severity of motor signs (aqua-based: MD -7.77, 95% CI -13.27 to -2.28; gait/balance/functional: MD -7.37, 95% CI -11.39 to -3.35; multi-domain: MD -6.97, 95% CI -10.32 to -3.62; low confidence). The evidence also suggests that mind-body training and endurance training might have a small beneficial effect on the severity of motor signs (mind-body: MD -6.57, 95% CI -10.18 to -2.81; endurance: MD -6.43, 95% CI -10.72 to -2.28; low confidence). Flexibility training might have a trivial or no effect on the severity of motor signs (MD 2.01, 95% CI -4.82 to 8.98; low confidence). The evidence is very uncertain about the effects of strength/resistance training and "Lee Silverman Voice training BIG" (LSVT BIG) on the severity of motor signs (strength/resistance: MD -6.97, 95% CI -11.93 to -2.01; LSVT BIG: MD -5.49, 95% CI -14.74 to 3.62; very low confidence). Quality of life The evidence from the NMA (55 studies; 3283 participants) suggests that aqua-based training probably has a large beneficial effect on QoL (MD -14.98, 95% CI -23.26 to -6.52; moderate confidence). The evidence also suggests that endurance training might have a moderate beneficial effect, and that gait/balance/functional and multi-domain training might have a small beneficial effect on QoL (endurance: MD -9.16, 95% CI -15.68 to -2.82; gait/balance/functional: MD -5.64, 95% CI -10.04 to -1.23; multi-domain: MD -5.29, 95% CI -9.34 to -1.06; low confidence). The evidence is very uncertain about the effects of mind-body training, gaming, strength/resistance training, dance, LSVT BIG, and flexibility training on QoL (mind-body: MD -8.81, 95% CI -14.62 to -3.00; gaming: MD -7.05, 95% CI -18.50 to 4.41; strength/resistance: MD -6.34, 95% CI -12.33 to -0.35; dance: MD -4.05, 95% CI -11.28 to 3.00; LSVT BIG: MD 2.29, 95% CI -16.03 to 20.44; flexibility: MD 1.23, 95% CI -11.45 to 13.92; very low confidence). Adverse events Only 85 studies (5192 participants) provided some kind of safety data, mostly only for the intervention groups. No adverse events (AEs) occurred in 40 studies and no serious AEs occurred in four studies. AEs occurred in 28 studies. The most frequently reported events were falls (18 studies) and pain (10 studies). The evidence is very uncertain about the effect of physical exercise on the risk of adverse events (very low confidence). Across outcomes, we observed little evidence of differences between exercise types. We found evidence of beneficial effects on the severity of motor signs and QoL for most types of physical exercise for people with PD included in this review, but little evidence of differences between these interventions. Thus, our review highlights the importance of physical exercise regarding our primary outcomes severity of motor signs and QoL, while the exact exercise type might be secondary. Notably, this conclusion is consistent with the possibility that specific motor symptoms may be treated most effectively by PD-specific programs. Although the evidence is very uncertain about the effect of exercise on the risk of adverse events, the interventions included in our review were described as relatively safe. Larger, well-conducted studies are needed to increase confidence in the evidence. Additional studies recruiting people with advanced disease severity and cognitive impairment might help extend the generalizability of our findings to a broader range of people with PD.

Sections du résumé

BACKGROUND
Physical exercise is effective in managing Parkinson's disease (PD), but the relative benefit of different exercise types remains unclear.
OBJECTIVES
To compare the effects of different types of physical exercise in adults with PD on the severity of motor signs, quality of life (QoL), and the occurrence of adverse events, and to generate a clinically meaningful treatment ranking using network meta-analyses (NMAs).
SEARCH METHODS
An experienced information specialist performed a systematic search for relevant articles in CENTRAL, MEDLINE, Embase, and five other databases to 17 May 2021. We also searched trial registries, conference proceedings, and reference lists of identified studies up to this date.
SELECTION CRITERIA
We included randomized controlled trials (RCTs) comparing one type of physical exercise for adults with PD to another type of exercise, a control group, or both.
DATA COLLECTION AND ANALYSIS
Two review authors independently extracted data. A third author was involved in case of disagreements.  We categorized the interventions and analyzed their effects on the severity of motor signs, QoL, freezing of gait, and functional mobility and balance up to six weeks after the intervention using NMAs. Two review authors independently assessed the risk of bias using the risk of bias 2 (RoB 2) tool and rated the confidence in the evidence using the CINeMA approach for results on the severity of motor signs and QoL. We consulted a third review author to resolve any disagreements. Due to heterogeneous reporting of adverse events, we summarized safety data narratively and rated our confidence in the evidence using the GRADE approach.
MAIN RESULTS
We included 156 RCTs with a total of 7939 participants with mostly mild to moderate disease and no major cognitive impairment. The number of participants per study was small (mean 51, range from 10 to 474). The NMAs on the severity of motor signs and QoL included data from 71 (3196 participants), and 55 (3283 participants) trials, respectively. Eighty-five studies (5192 participants) provided safety data. Here, we present the main results. We observed evidence of beneficial effects for most types of physical exercise included in our review compared to a passive control group. The effects on the severity of motor signs and QoL are expressed as scores on the motor scale of the Unified Parkinson Disease Rating Scale (UPDRS-M) and the Parkinson's Disease Questionnaire 39 (PDQ-39), respectively. For both scales, higher scores denote higher symptom burden. Therefore, negative estimates reflect improvement (minimum clinically important difference: -2.5 for UPDRS-M and -4.72 for PDQ-39). Severity of motor signs The evidence from the NMA (71 studies; 3196 participants) suggests that dance has a moderate beneficial effect on the severity of motor signs (mean difference (MD) -10.32, 95% confidence interval (CI) -15.54 to -4.96; high confidence), and aqua-based, gait/balance/functional, and multi-domain training might have a moderate beneficial effect on the severity of motor signs (aqua-based: MD -7.77, 95% CI -13.27 to -2.28; gait/balance/functional: MD -7.37, 95% CI -11.39 to -3.35; multi-domain: MD -6.97, 95% CI -10.32 to -3.62; low confidence). The evidence also suggests that mind-body training and endurance training might have a small beneficial effect on the severity of motor signs (mind-body: MD -6.57, 95% CI -10.18 to -2.81; endurance: MD -6.43, 95% CI -10.72 to -2.28; low confidence). Flexibility training might have a trivial or no effect on the severity of motor signs (MD 2.01, 95% CI -4.82 to 8.98; low confidence). The evidence is very uncertain about the effects of strength/resistance training and "Lee Silverman Voice training BIG" (LSVT BIG) on the severity of motor signs (strength/resistance: MD -6.97, 95% CI -11.93 to -2.01; LSVT BIG: MD -5.49, 95% CI -14.74 to 3.62; very low confidence). Quality of life The evidence from the NMA (55 studies; 3283 participants) suggests that aqua-based training probably has a large beneficial effect on QoL (MD -14.98, 95% CI -23.26 to -6.52; moderate confidence). The evidence also suggests that endurance training might have a moderate beneficial effect, and that gait/balance/functional and multi-domain training might have a small beneficial effect on QoL (endurance: MD -9.16, 95% CI -15.68 to -2.82; gait/balance/functional: MD -5.64, 95% CI -10.04 to -1.23; multi-domain: MD -5.29, 95% CI -9.34 to -1.06; low confidence). The evidence is very uncertain about the effects of mind-body training, gaming, strength/resistance training, dance, LSVT BIG, and flexibility training on QoL (mind-body: MD -8.81, 95% CI -14.62 to -3.00; gaming: MD -7.05, 95% CI -18.50 to 4.41; strength/resistance: MD -6.34, 95% CI -12.33 to -0.35; dance: MD -4.05, 95% CI -11.28 to 3.00; LSVT BIG: MD 2.29, 95% CI -16.03 to 20.44; flexibility: MD 1.23, 95% CI -11.45 to 13.92; very low confidence). Adverse events Only 85 studies (5192 participants) provided some kind of safety data, mostly only for the intervention groups. No adverse events (AEs) occurred in 40 studies and no serious AEs occurred in four studies. AEs occurred in 28 studies. The most frequently reported events were falls (18 studies) and pain (10 studies). The evidence is very uncertain about the effect of physical exercise on the risk of adverse events (very low confidence). Across outcomes, we observed little evidence of differences between exercise types.
AUTHORS' CONCLUSIONS
We found evidence of beneficial effects on the severity of motor signs and QoL for most types of physical exercise for people with PD included in this review, but little evidence of differences between these interventions. Thus, our review highlights the importance of physical exercise regarding our primary outcomes severity of motor signs and QoL, while the exact exercise type might be secondary. Notably, this conclusion is consistent with the possibility that specific motor symptoms may be treated most effectively by PD-specific programs. Although the evidence is very uncertain about the effect of exercise on the risk of adverse events, the interventions included in our review were described as relatively safe. Larger, well-conducted studies are needed to increase confidence in the evidence. Additional studies recruiting people with advanced disease severity and cognitive impairment might help extend the generalizability of our findings to a broader range of people with PD.

Identifiants

pubmed: 36602886
doi: 10.1002/14651858.CD013856.pub2
doi:

Banques de données

ClinicalTrials.gov
['NCT04012086', 'NCT02488265', 'NCT00750945', 'NCT03079817', 'NCT02509611', 'NCT00591344', 'NCT01388556', 'NCT02622737', 'NCT03213873', 'NCT00982709', 'NCT02231073', 'NCT02236286', 'NCT00611481', 'NCT04048291', 'NCT01701128', 'NCT02807740', 'NCT01120392', 'NCT02999997', 'NCT01573260', 'NCT02966600', 'NCT03235284', 'NCT01257945', 'NCT01506479', 'NCT02253563', 'NCT01939717', 'NCT02302144', 'NCT03193268', 'NCT03189680', 'NCT02902510', 'NCT02418780', 'NCT01799681', 'NCT01301651', 'NCT03689764', 'NCT03882398', 'NCT03463330', 'NCT03637023', 'NCT04291027', 'NCT02593955', 'NCT03495193', 'NCT00004760', 'NCT00029809', 'NCT00167453', 'NCT00387218', 'NCT01014663', 'NCT01076712', 'NCT01246700', 'NCT01427062', 'NCT01439022', 'NCT01562496', 'NCT01757509', 'NCT01835652', 'NCT01960985', 'NCT02017938', 'NCT02267785', 'NCT02419768', 'NCT02476240', 'NCT02476266', 'NCT02615548', 'NCT02656355', 'NCT02674724', 'NCT02745171', 'NCT02816619', 'NCT03212014', 'NCT03406728', 'NCT03443752', 'NCT03568903', 'NCT03618901', 'NCT01636297', 'NCT02457832', 'NCT03244813', 'NCT03343574', 'NCT03560089', 'NCT03563807', 'NCT03582371', 'NCT03711955', 'NCT03751371', 'NCT02885285', 'NCT03833349', 'NCT03860649', 'NCT03882879', 'NCT03960931', 'NCT03972969', 'NCT03974529', 'NCT03983785', 'NCT04000360', 'NCT04046276', 'NCT04063605', 'NCT04122690', 'NCT04135924', 'NCT04194762', 'NCT04215900', 'NCT04379778', 'NCT04558879', 'NCT04613141', 'NCT04644367', 'NCT04665869', 'NCT04699617', 'NCT04863118', 'NCT04872153', 'NCT04878679']

Types de publication

Meta-Analysis Systematic Review Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

CD013856

Informations de copyright

Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Références

Neurology. 2018 Nov 27;91(22):e2045-e2056
pubmed: 30381367
J Parkinsons Dis. 2017;7(1):203-210
pubmed: 28106568
Trends Cogn Sci. 2013 Oct;17(10):525-44
pubmed: 24029446
Clin Rehabil. 2018 Nov;32(11):1520-1529
pubmed: 29962227
Clin Rehabil. 2016 Jan;30(1):53-63
pubmed: 25697454
Arch Phys Med Rehabil. 2018 Dec;99(12):2478-2484.e1
pubmed: 29886075
Evid Based Complement Alternat Med. 2016;2016:5935782
pubmed: 27891159
Neurorehabil Neural Repair. 2015 Feb;29(2):103-11
pubmed: 24961993
J Neurol Sci. 2020 Nov 15;418:117086
pubmed: 32891018
ISRN Neurol. 2013 Oct 31;2013:548240
pubmed: 24294526
Disabil Rehabil. 2018 Apr;40(7):791-797
pubmed: 28084851
Front Neurol. 2020 Sep 04;11:790
pubmed: 33013612
Neurosciences (Riyadh). 2018 Jul;23(4):208-215
pubmed: 30007996
Stat Med. 2014 Nov 10;33(25):4353-69
pubmed: 24942211
Acta Neurol Belg. 2019 Jun;119(2):193-200
pubmed: 30413971
Complement Ther Med. 2018 Oct;40:248-252
pubmed: 30219460
Eur J Phys Rehabil Med. 2017 Oct;53(5):651-663
pubmed: 28290191
J Neurol Phys Ther. 2019 Jan;43(1):42-49
pubmed: 30531385
Phys Ther. 2011 Jun;91(6):862-74
pubmed: 21474638
Exp Brain Res. 2021 Mar;239(3):777-786
pubmed: 33394100
Physiotherapy. 2020 Mar;106:36-42
pubmed: 32026844
Age Ageing. 2001 Jul;30(4):299-302
pubmed: 11509307
Neurology. 2005 Oct 25;65(8):1239-45
pubmed: 16247051
NeuroRehabilitation. 2005;20(3):183-90
pubmed: 16340099
Lancet Neurol. 2006 Jun;5(6):525-35
pubmed: 16713924
Evid Based Complement Alternat Med. 2018 Jun 3;2018:8516351
pubmed: 29967649
Int J Environ Res Public Health. 2019 Dec 18;17(1):
pubmed: 31861456
NeuroRehabilitation. 2019;45(2):273-283
pubmed: 31561398
J Altern Complement Med. 2019 Mar;25(3):305-316
pubmed: 30624952
Trials. 2021 May 10;22(1):335
pubmed: 33971928
Complement Med Res. 2019;26(6):398-403
pubmed: 31266016
CMAJ. 2016 Nov 1;188(16):1157-1165
pubmed: 27221269
Lancet Neurol. 2010 Jan;9(1):46-54
pubmed: 19959398
Health Technol Assess. 2019 Jul;23(36):1-150
pubmed: 31339100
Parkinsons Dis. 2012;2012:508720
pubmed: 21941685
Cochrane Database Syst Rev. 2019 Jan 31;1:CD012424
pubmed: 30703272
Percept Mot Skills. 2021 Feb;128(1):304-323
pubmed: 32746736
Arch Phys Med Rehabil. 1986 Oct;67(10):741-5
pubmed: 3767624
Neurorehabil Neural Repair. 2020 Oct;34(10):871-880
pubmed: 32917125
Neurol Neurochir Pol. 2013 May-Jun;47(3):256-62
pubmed: 23821423
Am J Phys Med Rehabil. 2017 May;96(5):301-306
pubmed: 27584142
Front Aging Neurosci. 2021 Nov 18;13:739115
pubmed: 34867273
Qual Life Res. 1995 Jun;4(3):241-8
pubmed: 7613534
Arch Phys Med Rehabil. 2000 Jul;81(7):849-52
pubmed: 10895994
N Engl J Med. 2012 Feb 9;366(6):511-9
pubmed: 22316445
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
J Physiother. 2017 Apr;63(2):94-100
pubmed: 28342682
Parkinsonism Relat Disord. 2016 Feb;23:37-44
pubmed: 26698015
Gait Posture. 2012 Apr;35(4):669-73
pubmed: 22266107
J Neurochem. 2003 Apr;85(2):299-305
pubmed: 12675906
Ann Neurol. 1984 Sep;16(3):278-82
pubmed: 6333204
J Am Geriatr Soc. 1991 Feb;39(2):142-8
pubmed: 1991946
Parkinsonism Relat Disord. 2014 Jan;20(1):106-11
pubmed: 24209458
Complement Ther Med. 2017 Jun;32:91-97
pubmed: 28619310
Neurology. 1967 May;17(5):427-42
pubmed: 6067254
JAMA Neurol. 2013 Feb;70(2):183-90
pubmed: 23128427
PLoS One. 2020 Jul 30;15(7):e0236391
pubmed: 32730325
Mod Treat. 1968 Mar;5(2):257-82
pubmed: 5655944
J Rehabil Med. 2009 May;41(6):475-81
pubmed: 19479161
Mov Disord. 2020 Sep;35(9):1607-1617
pubmed: 32557868
J Am Geriatr Soc. 1998 Oct;46(10):1207-16
pubmed: 9777901
Parkinsons Dis. 2010 Mar 16;2010:824734
pubmed: 20976096
Parkinsons Dis. 2012;2012:360231
pubmed: 22046578
Nat Neurosci. 2009 Mar;12(3):333-41
pubmed: 19198605
PM R. 2014 Jan;6(1):22-33
pubmed: 24021298
Mov Disord. 1997 May;12(3):306-14
pubmed: 9159724
J Bodyw Mov Ther. 2017 Apr;21(2):414-421
pubmed: 28532886
Evid Based Complement Alternat Med. 2021 Mar 29;2021:8833736
pubmed: 33859712
Funct Neurol. 2016 Jan-Mar;31(1):25-31
pubmed: 27027891
Gait Posture. 2017 Feb;52:87-94
pubmed: 27888696
BMC Health Serv Res. 2012 Nov 23;12:426
pubmed: 23176532
JAMA Neurol. 2018 Feb 1;75(2):219-226
pubmed: 29228079
Clin Rehabil. 2014 Mar;28(3):275-88
pubmed: 24188914
Brain. 1999 Aug;122 ( Pt 8):1437-48
pubmed: 10430830
Mov Disord. 2012 Jan;27(1):143-6
pubmed: 21953509
J Funct Morphol Kinesiol. 2020 Nov 10;5(4):
pubmed: 33467297
Arch Phys Med Rehabil. 2016 Mar;97(3):345-354.e15
pubmed: 26546987
Parkinsonism Relat Disord. 2017 May;38:13-18
pubmed: 28190675
Complement Ther Clin Pract. 2020 May;39:101169
pubmed: 32379638
J Neurol Phys Ther. 2019 Jan;43(1):26-32
pubmed: 30531383
Cochrane Database Syst Rev. 2013 Sep 10;(9):CD002817
pubmed: 24018704
Scand J Med Sci Sports. 2019 Dec;29(12):1957-1967
pubmed: 31357229
Aging Clin Exp Res. 2021 Dec;33(12):3275-3284
pubmed: 33978924
Clin Rehabil. 2014 Sep;28(9):902-11
pubmed: 24691217
J Aging Res. 2011;2011:232473
pubmed: 21603199
Arch Phys Med Rehabil. 2005 Apr;86(4):626-32
pubmed: 15827910
Mov Disord. 2009 Jan 15;24(1):64-71
pubmed: 18942100
Lancet Neurol. 2016 Nov;15(12):1257-1272
pubmed: 27751556
Parkinsons Dis. 2012;2012:795294
pubmed: 22191076
Mov Disord. 2015 Oct;30(12):1657-63
pubmed: 26148003
NeuroRehabilitation. 2015;37(2):245-54
pubmed: 26484516
Neurology. 2015 Jan 20;84(3):304-12
pubmed: 25552576
Parkinsonism Relat Disord. 2013 Nov;19(11):955-60
pubmed: 23835431
Neurorehabil Neural Repair. 2014 Feb;28(2):163-8
pubmed: 24213955
Trials. 2011 May 17;12:125
pubmed: 21586143
J Neurol. 2022 Jun;269(6):3310-3324
pubmed: 35244766
NeuroRehabilitation. 2019;44(4):579-586
pubmed: 31256094
Arq Neuropsiquiatr. 2018 Aug;76(8):499-506
pubmed: 30231121
Ann Phys Rehabil Med. 2021 Jan;64(1):101407
pubmed: 32561505
Trials. 2009 Aug 11;10:67
pubmed: 19671145
Mov Disord. 2013 Aug;28(9):1230-40
pubmed: 23536417
Clin Rehabil. 2020 Apr;34(4):533-544
pubmed: 32070122
Arch Neurol. 2010 Jan;67(1):64-70
pubmed: 20065131
Arch Phys Med Rehabil. 2021 May;102(5):925-931
pubmed: 33453190
Front Neurol. 2019 Aug 29;10:902
pubmed: 31543859
Neurorehabil Neural Repair. 2012 Feb;26(2):132-43
pubmed: 21959675
Arch Neurol. 1969 Oct;21(4):343-54
pubmed: 5820999
Clin Auton Res. 2014 Jun;24(3):111-8
pubmed: 24659140
Parkinsonism Relat Disord. 2017 May;38:8-12
pubmed: 28202374
Lancet. 2021 Jun 12;397(10291):2284-2303
pubmed: 33848468
J Parkinsons Dis. 2021;11(3):1431-1441
pubmed: 33967056
Front Neurol. 2020 Jul 24;11:656
pubmed: 32793096
Trials. 2017 Nov 2;18(1):509
pubmed: 29096672
Parkinsons Dis. 2019 Mar 03;2019:4076862
pubmed: 30944720
Gait Posture. 2018 Mar;61:90-97
pubmed: 29310015
Clin Rehabil. 2017 Aug;31(8):1107-1115
pubmed: 27512099
PLoS One. 2015 Oct 26;10(10):e0140584
pubmed: 26501562
Int J Yoga Therap. 2019 Nov;29(1):91-99
pubmed: 30901529
J Neurol Neurosurg Psychiatry. 2016 Sep;87(9):952-7
pubmed: 26701996
Clin Rehabil. 2017 Oct;31(10):1340-1350
pubmed: 28933613
Acta Neurol Scand. 2022 May;145(5):504-528
pubmed: 34997759
NPJ Parkinsons Dis. 2020 Nov 2;6(1):31
pubmed: 33298934
J Clin Epidemiol. 2006 Jan;59(1):7-10
pubmed: 16360555
Parkinsonism Relat Disord. 2000 Jul 1;6(3):165-170
pubmed: 10817956
Lancet Public Health. 2020 Oct;5(10):e551-e567
pubmed: 33007212
J Parkinsons Dis. 2020;10(1):325-332
pubmed: 31868684
BMC Neurol. 2015 Sep 07;15:162
pubmed: 26347052
Arch Phys Med Rehabil. 2003 Aug;84(8):1109-17
pubmed: 12917847
J Neurol Neurosurg Psychiatry. 2007 Jul;78(7):678-84
pubmed: 17119004
Am J Phys Med Rehabil. 2018 Mar;97(3):151-159
pubmed: 29095706
J Parkinsons Dis. 2020;10(1):333-346
pubmed: 31884492
Ann Intern Med. 2015 Jun 2;162(11):777-84
pubmed: 26030634
Parkinsons Dis. 2020 Sep 8;2020:2565320
pubmed: 32963753
Complement Ther Med. 2018 Feb;36:147-153
pubmed: 29458923
Rejuvenation Res. 2020 Dec;23(6):508-515
pubmed: 32336211
Eur J Neurol. 2010 Sep;17(9):1156-1163
pubmed: 20345926
Arch Phys Med Rehabil. 2017 Sep;98(9):1744-1751
pubmed: 28336345
Clin Rehabil. 2014 Dec;28(12):1210-7
pubmed: 24895382
Gerontology. 2019;65(2):120-127
pubmed: 30368495
Res Synth Methods. 2021 Jan;12(1):55-61
pubmed: 32336025
Arch Phys Med Rehabil. 2008 Jul;89(7):1221-9
pubmed: 18534554
Mov Disord. 2008 Nov 15;23(15):2129-70
pubmed: 19025984
Complement Ther Med. 2016 Apr;25:126-31
pubmed: 27062960
Trauma Mon. 2016 Feb 06;21(1):e23573
pubmed: 27218051
Mov Disord. 2015 Oct;30(12):1591-601
pubmed: 26474316
Parkinsons Dis. 2019 Aug 7;2019:8769141
pubmed: 31485305
Clin Interv Aging. 2015 Jan 07;10:183-91
pubmed: 25609935
Int J Yoga Therap. 2018 Nov;28(1):51-61
pubmed: 29630416
Clin Rehabil. 2020 Dec;34(12):1425-1435
pubmed: 32715810
Aging Clin Exp Res. 2016 Dec;28(6):1169-1177
pubmed: 26661467
Sci Rep. 2017 Apr 04;8:45865
pubmed: 28374775
Medicina (Kaunas). 2020 Jul 17;56(7):
pubmed: 32708938
J Complement Integr Med. 2019 Aug 21;17(1):
pubmed: 31433785
Parkinsonism Relat Disord. 2015 Jun;21(6):615-21
pubmed: 25899544
J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181-4
pubmed: 1564476
J Parkinsons Dis. 2017;7(3):533-543
pubmed: 28671140
J Gerontol. 1990 Nov;45(6):P239-43
pubmed: 2229948
Parkinsonism Relat Disord. 2009 Nov;15(9):644-8
pubmed: 19329350
Am J Phys Med Rehabil. 2015 Oct;94(10 Suppl 1):921-9
pubmed: 26135376
Lancet Neurol. 2018 Nov;17(11):939-953
pubmed: 30287051
Arch Phys Med Rehabil. 2015 Dec;96(12):2103-11
pubmed: 26299751
Phys Ther. 2011 Jan;91(1):114-21
pubmed: 20947672
NeuroRehabilitation. 2019;45(2):255-263
pubmed: 31498138
J Neurol Neurosurg Psychiatry. 1996 Jul;61(1):70-4
pubmed: 8676165
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
Gait Posture. 2009 Nov;30(4):459-63
pubmed: 19660949
Neuroepidemiology. 2017;48(1-2):1-8
pubmed: 28161701
Complement Ther Med. 2019 Feb;42:119-124
pubmed: 30670228
Mov Disord. 2011 Feb 15;26(3):399-406
pubmed: 21264941
Aging Clin Exp Res. 2021 Apr;33(4):965-971
pubmed: 32529596
Acta Neurol Belg. 2021 Apr;121(2):535-543
pubmed: 31741209
J Pers Med. 2021 Apr 30;11(5):
pubmed: 33946172
Mov Disord. 2009 Jun 15;24(8):1132-8
pubmed: 19373930
Trials. 2018 Nov 14;19(1):630
pubmed: 30428907
Mov Disord. 2020 Jun;35(6):947-958
pubmed: 32092190
Neural Plast. 2020 Mar 5;2020:8961493
pubmed: 32256559
NeuroRehabilitation. 2013;32(1):125-34
pubmed: 23422465
Mov Disord. 2014 Apr;29(4):539-45
pubmed: 24375468
Arch Phys Med Rehabil. 2002 Oct;83(10):1370-3
pubmed: 12370870
J Neuroeng Rehabil. 2020 Jul 13;17(1):91
pubmed: 32660512
J Appl Physiol (1985). 2017 Jan 1;122(1):1-10
pubmed: 27834670
BMJ. 2019 Aug 28;366:l4898
pubmed: 31462531
J Neurol Neurosurg Psychiatry. 2007 Feb;78(2):134-40
pubmed: 17229744
J Strength Cond Res. 2017 Aug;31(8):2270-2277
pubmed: 27787472
Clin Interv Aging. 2020 Jan 23;15:87-95
pubmed: 32158202
Int J Yoga Therap. 2020 Jan 1;30(1):41-48
pubmed: 31584838
Arch Phys Med Rehabil. 2015 Sep;96(9):1557-65
pubmed: 26008873
Parkinsons Dis. 2013;2013:572134
pubmed: 23738230
Clin Rehabil. 2019 Feb;33(2):222-232
pubmed: 30246557
Parkinsonism Relat Disord. 2020 Aug;77:18-19
pubmed: 32575003
Med Clin (Barc). 2018 Jun 22;150(12):460-464
pubmed: 29173985
Clin J Sport Med. 2008 May;18(3):289-91
pubmed: 18469574
PLoS One. 2020 Aug 5;15(8):e0236820
pubmed: 32756578
Med Sci Monit. 2019 Jun 05;25:4186-4192
pubmed: 31165721
Neurology. 1997 Nov;49(5):1284-8
pubmed: 9371909
BMC Geriatr. 2013 Jun 04;13:54
pubmed: 23731986
J Sports Med Phys Fitness. 2019 Oct;59(10):1756-1762
pubmed: 31113177
Disabil Rehabil. 2017 Aug;39(16):1573-1580
pubmed: 27416005
Rehabil Res Pract. 2013;2013:375267
pubmed: 23853722
Cochrane Database Syst Rev. 2023 Jan 5;1:CD013856
pubmed: 36602886
Arch Phys Med Rehabil. 2014 May;95(5):996-9
pubmed: 24231400
J Neurol Phys Ther. 2019 Apr;43(2):96-105
pubmed: 30883497
Mov Disord. 2008 Mar 15;23(4):501-9
pubmed: 18074365
Neurorehabil Neural Repair. 2020 May;34(5):417-427
pubmed: 32249668
Complement Ther Med. 2015 Apr;23(2):210-9
pubmed: 25847558
NPJ Parkinsons Dis. 2021 Sep 10;7(1):81
pubmed: 34508083
J Neurol Phys Ther. 2016 Jan;40(1):24-30
pubmed: 26655100
Int J Prev Med. 2019 Aug 12;10:131
pubmed: 31516672
Clin Rehabil. 2014 Feb 11;28(8):748-753
pubmed: 24519923
Aging Clin Exp Res. 2018 Jul;30(7):727-735
pubmed: 28980176
Expert Rev Neurother. 2014 Jan;14(1):93-103
pubmed: 24328720
Eur J Phys Rehabil Med. 2017 Apr;53(2):173-183
pubmed: 27879959
Neurorehabil Neural Repair. 2014 Jul;28(6):524-35
pubmed: 24407915
Clin Rehabil. 2012 Sep;26(9):817-26
pubmed: 22257506
Mov Disord. 2006 Apr;21(4):543-8
pubmed: 16229022
Am J Epidemiol. 2022 Mar 24;191(5):930-938
pubmed: 35146500
Complement Ther Med. 2015 Apr;23(2):175-84
pubmed: 25847555
Med Sci Sports Exerc. 2016 Sep;48(9):1678-87
pubmed: 27054681
Neuropsychology. 2019 Feb;33(2):147-156
pubmed: 30407031
BMC Neurol. 2020 May 13;20(1):186
pubmed: 32404132
J Geriatr Phys Ther. 2023 Apr-Jun 01;46(2):E87-E105
pubmed: 34392264
Sci Rep. 2016 Sep 13;6:33242
pubmed: 27628128
Mov Disord. 1996 Mar;11(2):193-200
pubmed: 8684391
Parkinsons Dis. 2019 Dec 27;2019:3846279
pubmed: 32089815
Stat Med. 2010 Mar 30;29(7-8):932-44
pubmed: 20213715
Front Neurol. 2020 Oct 09;11:943
pubmed: 33162925
Phys Ther. 2012 Nov;92(11):1395-410
pubmed: 22822237
PLoS Med. 2020 Apr 3;17(4):e1003082
pubmed: 32243458
Clin Rehabil. 2007 Aug;21(8):698-705
pubmed: 17846069
Mov Disord. 2010 Jul 15;25(9):1217-25
pubmed: 20629134
Lancet Neurol. 2019 Nov;18(11):998-1008
pubmed: 31521532
Int J Yoga. 2015 Jan;8(1):74-9
pubmed: 25558138
Neurol Sci. 2016 Apr;37(4):515-22
pubmed: 26700803
J Neurol Neurosurg Psychiatry. 2018 Aug;89(8):828-835
pubmed: 29321141
Res Synth Methods. 2012 Dec;3(4):312-24
pubmed: 26053424
J Strength Cond Res. 2017 Oct;31(10):2866-2875
pubmed: 27893480
Arch Phys Med Rehabil. 2017 Apr;98(4):631-638
pubmed: 28088380
Parkinsons Dis. 2015;2015:586378
pubmed: 25722915
Med Sci Sports Exerc. 2014 Apr;46(4):645-55
pubmed: 24002341
J Clin Med. 2020 Jan 09;9(1):
pubmed: 31936624
J Yoga Phys Ther. 2013 Aug 20;3:
pubmed: 24278789
Gait Posture. 2008 Oct;28(3):456-60
pubmed: 18378456
Am J Phys Med Rehabil. 2019 Mar;98(3):239-244
pubmed: 30211719
Brain Cogn. 2018 Apr;122:1-8
pubmed: 29331916
Neurorehabil Neural Repair. 2015 Sep;29(8):777-85
pubmed: 25567121
Ther Adv Neurol Disord. 2021 Feb 18;14:1756286420986744
pubmed: 33680093
Disabil Rehabil. 2013;35(26):2197-204
pubmed: 23480646
NeuroRehabilitation. 2013;32(1):117-24
pubmed: 23422464
Front Biosci (Landmark Ed). 2018 Jan 1;23(1):162-182
pubmed: 28930542
Explore (NY). 2018 May - Jun;14(3):216-223
pubmed: 29650371
J Neurol Phys Ther. 2007 Dec;31(4):173-9
pubmed: 18172414
Health Policy. 1990 Dec;16(3):199-208
pubmed: 10109801
Med Sci Sports Exerc. 2019 Feb;51(2):237-245
pubmed: 30303934
J Multidiscip Healthc. 2021 Apr 28;14:941-950
pubmed: 33953563
J Neurol Phys Ther. 2017 Jan;41(1):21-30
pubmed: 27977518
Sensors (Basel). 2020 Jul 23;20(15):
pubmed: 32717956
Med Sci Sports Exerc. 2017 Apr;49(4):652-660
pubmed: 27851668
Neurorehabil Neural Repair. 2015 Feb;29(2):112-22
pubmed: 24961994
J Neurosci. 2007 May 16;27(20):5291-300
pubmed: 17507552
Cochrane Database Syst Rev. 2014 Jun 17;(6):CD002815
pubmed: 24936965
J Physiother. 2019 Apr;65(2):65-74
pubmed: 30904467
Parkinsonism Relat Disord. 2007 Mar;13(2):115-21
pubmed: 17055767
J Neurol Neurosurg Psychiatry. 2019 Jul;90(7):774-782
pubmed: 30944149
Cochrane Database Syst Rev. 2016 Dec 21;12:CD010760
pubmed: 28000926
Geriatr Gerontol Int. 2016 Aug;16(8):911-9
pubmed: 26310941
BMC Med Res Methodol. 2015 Jul 31;15:58
pubmed: 26227148
NeuroRehabilitation. 2000;14(3):165-174
pubmed: 11455079
Age Ageing. 1997 Sep;26(5):353-7
pubmed: 9351479
Mov Disord. 2008 Apr 15;23(5):631-40
pubmed: 18181210
Health Expect. 2021 Apr;24(2):566-577
pubmed: 33591629
Parkinsonism Relat Disord. 2017 Oct;43:20-26
pubmed: 28673611
Clin Rehabil. 2019 Mar;33(3):428-438
pubmed: 30514114
J Neurol Phys Ther. 2005 Mar;29(1):2-8
pubmed: 16386155
Am J Phys Med Rehabil. 2010 Sep;89(9):706-14
pubmed: 20581650
Pilot Feasibility Stud. 2018 Oct 23;4:162
pubmed: 30377537
Nat Rev Neurol. 2017 Nov;13(11):689-703
pubmed: 29027544
J Clin Neurosci. 2019 Dec;70:47-54
pubmed: 31526677
Neurorehabil Neural Repair. 2015 Feb;29(2):123-31
pubmed: 25038064
Phys Ther. 2020 Oct 30;100(11):2023-2034
pubmed: 32737973
Arch Phys Med Rehabil. 2017 Nov;98(11):2134-2141
pubmed: 28705551
Eura Medicophys. 2006 Sep;42(3):231-8
pubmed: 17039221
J Neurol Phys Ther. 2015 Jul;39(3):179-84
pubmed: 26050074
Arch Phys Med Rehabil. 2013 Feb;94(2):240-9
pubmed: 22902795
Glob Adv Health Med. 2018 May 17;7:2164956118775385
pubmed: 29796338
Neurorehabil Neural Repair. 2012 May;26(4):353-61
pubmed: 22258155
J Exerc Rehabil. 2016 Oct 31;12(5):499-503
pubmed: 27807532
Eur J Phys Rehabil Med. 2017 Dec;53(6):825-832
pubmed: 28627861
Mov Disord. 2001 May;16(3):507-10
pubmed: 11391746
J Neurol Neurosurg Psychiatry. 2011 Nov;82(11):1232-8
pubmed: 21856692
J Sports Med Phys Fitness. 2020 Feb;60(2):282-288
pubmed: 31665879
Geriatr Gerontol Int. 2019 Jul;19(7):635-640
pubmed: 31037806
Arch Phys Med Rehabil. 2018 May;99(5):826-833
pubmed: 29337023
Nat Rev Dis Primers. 2021 Jul 1;7(1):47
pubmed: 34210995
Neurorehabil Neural Repair. 2010 Nov-Dec;24(9):826-34
pubmed: 21045119
JAMA Neurol. 2019 Jul 1;76(7):755-763
pubmed: 30958514
Neurorehabil Neural Repair. 2015 Aug;29(7):658-67
pubmed: 25539782
Mov Disord. 2010 Sep 15;25(12):1902-8
pubmed: 20669294
Parkinsons Dis. 2020 Jul 09;2020:3257623
pubmed: 32695306
Front Neurol. 2018 Dec 10;9:1084
pubmed: 30619044
Neurorehabil Neural Repair. 2015 Oct;29(9):827-36
pubmed: 25608520
Neurorehabil Neural Repair. 2012 Feb;26(2):144-50
pubmed: 21844282
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2013 Nov;38(11):1172-6
pubmed: 24316936
Mov Disord. 2020 Apr;35(4):523-536
pubmed: 31799734
Arch Phys Med Rehabil. 2011 Aug;92(8):1202-10
pubmed: 21807139
BMJ Open. 2020 Oct 12;10(10):e039941
pubmed: 33046475

Auteurs

Moritz Ernst (M)

Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.

Ann-Kristin Folkerts (AK)

Medical Psychology, Neuropsychology and Gender Studies and Center for Neuropsychological Diagnostics and Intervention (CeNDI), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.

Romina Gollan (R)

Medical Psychology, Neuropsychology and Gender Studies and Center for Neuropsychological Diagnostics and Intervention (CeNDI), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.

Emma Lieker (E)

Medical Psychology, Neuropsychology and Gender Studies and Center for Neuropsychological Diagnostics and Intervention (CeNDI), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.

Julia Caro-Valenzuela (J)

Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.

Anne Adams (A)

Institute of Medical Statistics and Computational Biology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.

Nora Cryns (N)

Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.

Ina Monsef (I)

Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.

Antje Dresen (A)

Institute of Medical Sociology, Health Services Resarch, and Rehabilitation Science (IMVR), Faculty of Human Sciences and Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.

Mandy Roheger (M)

Ambulatory Assessment in Psychology, Department of Psychology, Carl von Ossietzky University Oldenburg, Oldenburg, Germany.

Carsten Eggers (C)

Department of Neurology, University Hospital Marburg, Marburg, Germany.
Department of Neurology, Knappschaftskrankenhaus Bottrop GmbH, Bottrop, Germany.

Nicole Skoetz (N)

Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.

Elke Kalbe (E)

Medical Psychology, Neuropsychology and Gender Studies and Center for Neuropsychological Diagnostics and Intervention (CeNDI), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH